A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL019 Administered to Subjects with Myeloproliferative Disorders.

Trial Profile

A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL019 Administered to Subjects with Myeloproliferative Disorders.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 04 Apr 2011

At a glance

  • Drugs XL 019 (Primary)
  • Indications Myelofibrosis
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Apr 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 21 Nov 2009 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
    • 08 Dec 2008 Interim results were presented at the 50th Annual Meeting of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top